Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059995 · ClinicalTrials.gov registry record · Phase 1
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00059995: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00059995 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059995, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma.
Interventions
- BIOLOGICAL iratumumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059995
The ClinicalTrials.gov registry entry for NCT00059995 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iratumumab is the first listed.
NCT00059995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059995 about?
NCT00059995 is a clinical study titled "MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma". RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or re...
What is the current status of trial NCT00059995?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00059995?
The interventions under investigation include: iratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00059995?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.